It has been demonstrated from several laboratories that there exists a number of antigen-nonspecific soluble factors that can transmit signals for growth and/or differentiation among various types of leukocytes and that thus play a potentially major role in the regulation of immune responses (1, 2). Certain studies have demonstrated that monocyte-derived interleukin 1 (IL-1) 1 induces certain thymusderived T cell subsets to secrete IL-2, which in turn can maintain the continuous in vitro proliferation of other T cell subsets (3, 4). In this regard, by using IL-2, it has recently become possible to maintain the long-term culture of antigen-specific mouse or human T cell clones (5-10).
It has been demonstrated from several laboratories that there exists a number of antigen-nonspecific soluble factors that can transmit signals for growth and/or differentiation among various types of leukocytes and that thus play a potentially major role in the regulation of immune responses (1, 2) . Certain studies have demonstrated that monocyte-derived interleukin 1 (IL-1) 1 induces certain thymusderived T cell subsets to secrete IL-2, which in turn can maintain the continuous in vitro proliferation of other T cell subsets (3, 4) . In this regard, by using IL-2, it has recently become possible to maintain the long-term culture of antigen-specific mouse or human T cell clones (5) (6) (7) (8) (9) (10) .
Compared with the use of IL-1 and IL-2 in T cell systems, the modulation of bone marrow-derived B cell activation, proliferation, and differentiation by soluble factors is poorly understood. Recent studies of the long-term culture of normal mouse and human B cells have indicated the existence of T cell-derived B cell growth factors (BCGF) that deliver signals to activated B cells to maintain a proliferative state (11) (12) (13) . Indeed, we and others have reported that there are separate signals required for B cell proliferation vs. differentiation in both the mouse and human models (14) (15) (16) (17) .
With regard to the sources of human BCGF, we have recently demonstrated that substantial BCGF activity was contained in culture supernatants of phytohemagglutinin (PHA)-stimulated human mononuclear cells (MNC) (18) and that BCGF and IL-2 elaborated by mitogen-stimulated peripheral blood T cells are separate molecules (19) . Finally, we have most recently developed a human T-T hybridoma that produces BCGF in the absence of other demonstrable T cell factor activity (20) . In the present study, using this monoclonal BCGF, we have examined the various activation signals required by purified human peripheral blood or tonsillar B cells for proliferative responses to BCGF. The data strongly suggest that there are at least two subsets of human B cells with regard to their relative susceptibility to proliferative signals delivered by BCGF, based on their state of in vivo activation.
Materials and Methods
Reagents. Purified PHA was obtained from Wellcome Research Laboratories, Beckenham, England. Pokeweed mitogen (PWM) was purchased from Gibco Laboratories, Grand Island Biological Co., Grand Island, NY. Staphylococcus aureus Cowan I (SAC) was prepared in our laboratory as previously described in detail (17) . F(ab')2 fragment goat anti-/x-specific antibody, F(ab')2 fragment nonimmunized goat IgG, fluorescein-eonjugated F(ab')2 fragment goat anti-/L human immunoglobulin (Ig) ~, 7, a, heavy, and light chains), fluorescein-eonjugated F(ab')2 fragment goat anti-mouse IgG, chromatographically purified human IgG, and human IgM, and F(ab')2 fragment rabbit anti-human Ig were purchased from N. L. Cappel Laboratories Inc., Cochranville, PA. A monoelonal antibody (4F2) was prepared in our laboratory as previously described (21, 22) .
Cell Preparations. Peripheral blood mononuclear cells (PBMC) from healthy donors were
separated by the standard Hypaque-Ficoll gradient method (18) . B cell-enriched (BCE) populations from PBMC were obtained by depletion of T cells and monocytes (18) . Briefly, T cells were depleted by twice rosetting with S-(2-aminoethyl)-isothiuronium bromide hydrobromide (AET)-treated sheep erythrocytes. Monocytes were depleted by adhering 50 × 108 T celldepleted cells to plastic flasks containing RPMI 1640 with 1% fetal calf serum (FCS) for 45 min at 37°C. Within this peripheral BCE population, there were 60-80% surface Ig (sIg)-positive cells as determined by staining with a fluorescein-conjugated F(ab')2 fragment goat anti-human Ig, and 8-20% monocytes as determined by nonspecific esterase staining (23) . Thus, sIg-positive cells were purified thoroughly by rosetting with ox erythrocytes coated with rabbit anti-human Ig (24) . Because this procedure reduced the monocytes to <1% and increased sIg-positive cells up to 80-90% in the BCE population, these sIg-positive cells were used as purified peripheral blood B cells. Human tonsils were obtained at tonsillectomy from 12-to 22-yr-old patients with chronic tonsillitis and were dispersed into single-cell suspensions (25) . BCE populations from tonsillar MNC were obtained by the methods described above. After two depletions of AET rosette-forming cells followed by depletion of plastic-adherent cells, there were 83-92% of sIgpositive cells and <0.1% of esterase-positive cells. Thus, this BCE population was used as purified tonsillar B cells. In certain experiments where indicated, tonsillar BCE suspensions were separated into fractions according to cell volume by using counterflow centrifugationelutriation (model J-6B, Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) by the method described previously in detail (26) with certain modifications (T. L. Gerrard and A. S. Fauci, unpublished observations). Briefly, 500 × 108 cells in 3 ml of elutriator buffer (phosphatebuffered saline added with 1.25% of human albumin and 50 /~g/ml of gentamycin) were injected into the elutriator chamber and spun with the J-6B elutriator at a constant speed of 2,020 _ 10 rpm, and the countercurrent flow rate was started at 7.5 ml/min and increased every 200 ml by 0.5-ml/min increments. Each 50-ml aliquot was collected from the exit part of the elutriator centrifuge. Cellular volume was measured with a Coulter Channelyzer (Coulter Electronics Inc., Hialeah, FL). Cells that were positive for 4F2 antigen were enumerated by treating cells with mouse monoclonal 4F2 antibody followed by incubating with fluoresceinconjugated F(ab')s goat anti-mouse IgG (27) . Sheep erythrocyte receptor-positive cells were enumerated by rosetting the cells with AET-treated sheep erythrocytes (18) .
BCGF Preparations.
Conventional BCGF was prepared as previously described from the supernatants of co-cultures of PBMC from two allogeneic donors in the presence of PHA (18) . Monoclonal BCGF was obtained from a human T-T cell hybridoma cell line, 2Bll, which had been established in our laboratory (20) . Cell-free supernatants were collected from unstimulated 2Bxl cells or a subclone of 2Bll, which showed substantial BCGF activity measured by the method described previously (18) . In this monoclonal BCGF preparation, there was no IL-2 activity as determined by measurement of [ZH]thymidine incorporation by an IL-2-dependent cell line as described by Farrar et al. (28) , and there was no T cell-replacing factor activity as determined by measurement of the induction of plaque-forming cells from SAC-stimulated normal B cells as described by Falkoff et al. (17) , or from the Epstein-Barr virus-transformed B blastoid cell line, CESS, described previously (29) .
B Cell Costimulatory Assay. A human B cell costimulatory assay was performed by the methods described for the murine model by Howard et al. (30) , with slight modifications. Briefly, purified B cells from peripheral blood or tonsillar MNC were cultured in 200/xl of RPMI 1640 containing 10% FCS (Dutchland Laboratories, Inc., Denver, PA), 5 × 10 -5 M 2-mercaptoethanol, penicillin (100/~g/ml), and streptomycin (100/~g/ml) in flat-bottomed 96-well microtiter plates (Costar, Data Packaging, Cambridge, MA) at densities as indicated in each experiment. Some cultures contained F'(ab')2 fragment goat anti-human/~ antibody (1-75 /~g antibody/ml), F(ab')2 fragment nonimmunized goat IgG (15-150/~g/ml), soluble human IgM or IgG (4-1,000 iug/ml), and/or various dilutions of the BCGF preparation as indicated. Cultures were incubated in 100% humidity in 5% CO2 in air at 37°C. In the standard proliferation assays, the cultures were pulsed with 1/~Ci of [3H]thymidine (6.7 Ci/mM; New England Nuclear, Boston, MA) over the last [16] [17] [18] [19] [20] 
Results
Effect of BCGF on Co-culture of Peripheral Blood B Cells with Soluble Anti-I~ Antibody. To determine the conditions for the co-culture system, 1 × 105 purified B cells from the peripheral blood of normal donors (enriched by the protocol described in Materials and Methods) were cultured with 15/~g/ml of F(ab')2 fraction of goat anti-bt antibody in the presence of BCGF (50 or 5% vol/vol). Substantial proliferation was observed only when both goat anti-/~ antibody and BCGF were added to the culture and not when either was added alone (Fig. 1 , groups E-H). This costimulatory effect of BCGF with goat anti-/~ antibody on B cell proliferation was found in the culture with not only monoclonal BCGF but also with conventional BCGF (PHA-conditioned medium), which was prepared by culturing allogeneic human MNC from two donors together with PHA for 96 h as previously described (18) . Purified B cells manifested substantial responses to the T cell-independent B cell mitogen, SAC, in the absence of added BCGF of a magnitude comparable to that of co-culture of anti-# antibody and BCGF. No response was observed to the T cell mitogen, PHA, in the presence or absence of added anti-# antibody.
Specific Binding of Anti-# Antibody to the IgM Receptor on B Cells.
To demonstrate the specific interaction between F(ab')2 goat anti-IgM antibody and membrane IgM, 1 X 105 purified peripheral blood B cells were co-cultured with F(ab')2 fragment goat anti-# antibody or with nonspecific F(ab')2 fragment goat Ig in the presence of BCGF (25% vol/vol). Although substantial B cell proliferative responses were observed by the co-culture with F(ab')2 fragment anti-# antibody, no proliferation was observed with F(abr)2 fragment nonspecific goat Ig (Table I , groups E-G).
In further attempts to define the specific binding of anti-# antibody to membrane IgM, we added soluble human IgM and IgG at various concentrations to cultures in which 1 × 105 freshly separated peripheral blood B ceils were co-cultured with anti-# antibody (15 #g/ml) and BCGF (25% vol/vol). Data in Fig. 2 demonstrate that, although 20 #g/ml of soluble IgM enhanced the incorporation of [aH]thymidine of B cells that were stimulated with anti-# antibody and BCGF, the incorporation was reduced to background levels with 100 #g/ml or more of soluble IgM. In contrast to IgM, the same concentration of IgG did not show any effect on anti-#-stimulated B cell proliferation. Furthermore, concentrations of 4-500 #g/ml of IgM had no effect on SAC-induced B cell proliferation, ruling out the possibility of nonspecific suppression of responses or of toxicity to B cells by these concentrations of IgM (data not shown). of BCGF in the presence of anti-/~ antibody (Fig. 3) . Thus, we used the monoclonal BCGF at a concentration of 25% vol/vol for the subsequent costimulatory assays. To study the relationship between B cell density in the microwell cultures used and the magnitude of proliferative responses of B cells, various numbers of purified B cells blood or tonsillar MNC were cultured with anti-/~ antibody (15/~g/ml) and BCGF (25% vol/vol) and assayed on day 3 for proliferation by measuring the incorporation of [3H]thymidine and on day 7 for maturation to Ig-secreting cells by measuring Ig (total IgM and IgG) in the culture supernatants by ELISA. As shown in Table II , tonsillar B cells cultured with PWM and irradiated T cells showed the expected polyclonal proliferative response concomitant with polyclonal Ig production, whereas B cells cultured with anti-/~ antibody and BCGF showed substantial proliferative responses without the induction of Ig production. This observation was also made in peripheral blood B cells stimulated with anti-~ antibody in the presence of BCGF. These data indicate that although costimulation with anti-hi antibody and monoclonal BCGF can induce blast transformation and DNA synthesis, it cannot induce maturation to Ig synthesis and secretion. BCGF based on the size of B cells, we used countercurrent centrifugation-elutriation (26) to obtain B cell populations of different sizes. The cell-size profile of two B cell subsets obtained by elutriation is demonstrated in Fig. 7 . Characterization of the surface markers of these unfractionated or fractionated purified tonsillar B cells is summarized in Table III . Of note is the fact that almost all of the cells in the fraction Fro. 7. Cell-size profile of two B cell subsets. Tonsillar BCE suspensions were separated into two fractions according to cell volume by using counterflow centrifugation-elutriation as described in Materials and Methods. Cellular volume was quantitated with a Coulter Channelyzer. of larger B cells (fraction 2) expressed not only slg but also the 4F2 antigen, which is a non-HLA, non-Ia cell-surface marker present on human monocytes and a subset of activated but not resting lymphocytes (21, 22) , whereas cells in the fraction of smaller B cells (fraction 1) did not express 4F2 antigen on their surface. These separate fractions were cultured with or without anti-# antibody (0.6-15/lg/ml) in the presence or absence of BCGF (25% vol/vol), and incorporation of [3H]thymidine was measured on day 3. Smaller cells (fraction 1) manifested substantial proliferative responses to costimulation with anti-# antibody and BCGF, but very little proliferation was observed with anti-/~ antibody or BCGF alone (Fig. 8) . Larger B cells (fraction 2) manifested substantial proliferative responses to BCGF without anti-/~ antibody, and the addition of anti-/~ antibody did not affect the response to BCGF (Fig. 8) . This observation indicates that small (presumably resting) B cells need at least two signals (anti-/~ antibody and BCGF) for initiation of proliferation, whereas large (activated) B cells need only one signal (BCGF) for initiation of proliferation or more likely for amplification of the low level of proliferation that had already been introduced in vivo. (16, 34) in the rabbit system and by Parker et al. (15) in the murine system, that anti-Ig antibody in the presence of T cell-derived factors induces Ig production in B cells. Since that time, anti-Ig antibody has been extensively used to selectively induce the proliferation of B cells, particularly in the murine system (35, 36) . However, this approach has been less successful in the human system and although there have been several reports of human B cell activation by anti-Ig, results have been controversial, probably because of the various types of anti-Ig antibodies used and the differing cellular requirements for activation (37) (38) (39) (40) .
Optimal Conditions for Synergistic Effect of Anti-# Antibody and BCGF on Peripheral

Relationship of Cell Size and State of In
In the present study, we used purified B cells from peripheral blood or tonsillar lymphocytes and the F(ab')2 fraction of goat anti-human IgM antibody. With low concentrations of goat anti-/~ antibody, the whole population of purified B cells manifested very little proliferation. However, a marked synergistic effect on B cell proliferation was noted with anti-# antibody in the presence of BCGF. Regarding the question of specific binding of anti-# antibody to the IgM receptor on B cells, it was demonstrated that the synergistic effect of anti-/~ antibody and BCGF on B cell proliferative responses was completely inhibited by the addition of soluble human IgM, but not by human IgG (Fig. 2) . It is not clear why the addition of 20 #g/ml of soluble IgM-enhanced anti-# induced B cell proliferation, but it is quite conceivable that the immune complexes made up of IgM and anti-# antibody enhance the lymphocyte proliferative responses, as previously described (41, 42) .
It has previously been reported that high concentrations of heterologous F(ab')2 fragment rabbit anti-# antibody induced B cell proliferation without a requirement for BCGF (40) . In that study, Chiorazzi et al. clearly demonstrated that in the absence of added BCGF, purified rabbit anti-human IgM or IgG antibodies induced proliferation of human tonsillar or peripheral blood B cells. The optimal concentration of antibody was 100-400 #g/ml. This requirement for a relatively high concentration of antibody to induce BCGF-independent B cell proliferation has also been reported in the murine system (35) . Furthermore, cross-linking of slg by large molecules such as the particulate SAC also resulted in BCGF-independent B cell proliferation (17) . In contrast, in the present study, low concentrations of anti-/1 antibody induced barely detectable levels of proliferation in tonsillar or peripheral blood B cells. In the presence of BCGF, however, these same low concentrations of anti-# antibody induced substantial proliferation (Figs. 5 and 6 ). This observation of synergy with low concentration anti-# antibody and BCGF is the same as that made in the murine model by Howard et al. (30) . Of note is the fact that higher concentrations of anti-/~ antibody in our system did indeed induce a certain degree of B cell proliferation in the absence of BCGF similar to the BCGF-independent proliferation reported by us (17, 18) with SAC and by Chiorazzi et al. (40) with high concentrations of rabbit anti-Ig. These observations fit quite well with a more precise delineation of the model of human B cell function proposed by us and others (18, 43) . It is likely that SAC or high concentrations of anti-Ig can provide a powerful enough signal for the B cell to not only be activated but also to undergo a degree of self-limited proliferation in the absence of BCGF. On the other hand, a weaker triggering signal such as low concentration anti-/~ antibody only provides an activation signal, without driving the cell to express the early rounds of proliferation. This signal can, however, induce the B cell to express receptors for BCGF (18) , which then allow it to respond synergistically to exogenous BCGF by substantial proliferation. Thus it appears that the strength of the initial activating signal in vitro determines whether the B cell will go on to proliferate (in the case of a strong stimulus) as well as whether there will be synergy with exogenous factors such as BCGF (as with weak stimuli). Furthermore, it was shown in the present study by using a low concentration of anti-/z stimulation that (a) as cell density in cultures decreases, anti-#-induced B cell proliferation is rapidly reduced to background levels ( Fig. 4 B) ; and (b) the synergistic effect ofanti-/~ antibody and BCGF was observed in cell densities as low as 7.8 X 10a/well, whereas no proliferation was observed with anti-/~ antibody alone (Fig. 4C) . This observation again strongly suggests the requirement of BCGF for a B cell proliferative response to a weaker triggering signal.
In the present study, costimulation of B cells with anti-# antibody and BCGF resulted in proliferation without differentiation into Ig-secreting cells (Table II) . In this regard, it has recently been reported that there are separate signals for B cell proliferation vs. differentiation in mouse (14) (15) (16) and in man (17, 18, 43) . We are currently studying differentiation factors derived from either mitogen-stimulated MNC cultures (29, 44) or human T-T cell hybridomas (20) which can induce differentiation in B cells stimulated with anti-/~ antibody and BCGF.
An observation of particular interest that emerged from the present study was that B cells were differentially sensitive on the basis of size to either the activation signal delivered by arati-# antibody or the proliferative signal delivered by BCGF. BCGF could directly stimulate larger B cells to proliferate even in the absence of the activation signal delivered by anti-~ antibody. In fact, anti-~ antibody did not at all increase the proliferative response of these larger B cells to BCGF, which strongly suggests that the activation signal was superfluous. Thus, it is highly likely that these larger tonsillar B cells were already activated in vivo; they certainly already expressed receptors for BCGF, since they proliferated quite well to BCGF alone. In fact, these larger B cells were shown to be already activated in that they expressed the 4F2 antigen (Table III) found on activated but not resting lymphocytes (J. H. Kerl and A. S. Fauci, manuscript in preparation) (21, 22) . In contrast, the smaller tonsillar lymphocytes did not respond to BCGF alone and hence did not express functional receptors for BCGF. Furthermore, they did not express the 4F2 activation antigen and they required activation by anti-/x antibody in order to respond by proliferation to BCGF. These data are consistent with those reported in the murine model by DeFranco et al. (45, 46) . These authors demonstrated that virtually all resting B cells were stimulated by low concentrations of anti-/t antibody to become larger (i.e., to proceed from Go phase to G1 phase of the cell cycle), and that a subpopulation of these cells entered S phase in response to high concentrations of anti-~ antibody or lipopolysaccharide. These latter reagents apparently acted directly on the B cells or stimulated other cells to produce BCGF, which may be the actual stimulus to G1 phase B cells to enter S phase (46 F[o. 9. Proposed scheme of human B cell activation and proliferation. In the in vivo situation, certain resting B ceils may be activated by exposure to specific antigen. Upon activation, the cells become larger and express receptors for growth factors. Thus when B cells are removed from the host, they are in various states of activation depending on prior exposure to these various activation signals in vivo. In the examination of the B cell repertoire in vitro, certain cells will have already been activated in vivo and thus will be larger and will express activation antigens such as 4F2. These activated cells are already sensitive to the proliferative signals delivered by BCGF and will in fact proliferate to BCGF without needing an in vitro activation signal such as stimulation with anti-IX antibody. Once these cells are exposed to BCGF, they will proliferate and go on to express receptors for a B cell differentiation factor termed BCDF. If exposed to BCDF, they will differentiate and secrete Ig. In contrast, the smaller resting B cell that has not received an activation signal in vivo is resistant to direct stimulation by BCGF and does not express the 4F2 activation antigen. Upon triggering with anti-Ix antibody, the resting B cell becomes larger, expresses the 4F2 antigen, and becomes sensitive to the proliferative signals to BCGF. It thus assumes the same profile of the B cell that had been activated in vivo. When this in vitro-activated B cell is exposed to BCGF, it proliferates, expresses receptors for BCDF, and will differentiate upon exposure to differentiation signals.
regard to the relationship between activation and proliferation (Fig. 9) . B cells require activation in order to express receptors for BCGF that are required for sustained proliferation. This activation signal can be delivered by either anti-It , which is the minimal activation signal that results in virtually no proliferation in the absence of 
Summary
The present study demonstrates the minimal, optimal, and synergistic signals involved in the activation of normal human peripheral blood and tonsillar B cells to proliferation. Initial activation signals were delivered to B cells by low concentrations of anti-# antibody which did not induce proliferation by themselves. However, marked synergy was seen when anti-# antibody was added to cultures in the presence of monoclonal B cell growth factor (BCGF) obtained from a human T-T cell hybrid such that the B cells underwent substantial proliferation. This latter proliferation was seen without maturation into Ig-secreting cells, which indicates that the BCGF is not a differentiation signal but a signal that drives the cell up to but not beyond the proliferative phase. Of note was the fact that B cells reflected differential sensitivity on the basis of size to either the activation signal delivered by anti-# antibody or the proliferative signal delivered by BCGF. BCGF directly stimulated the larger B cells in the normal tonsillar B cell repertoire to proliferate without the requirement for an in vitro activation signal, which indicates that the cells had already received some form of activation signal in vivo. Indeed, these cells expressed the 4F2 antigen found on activated but not resting lymphocytes. In contrast, the smaller tonsillar B lymphocytes did not express the 4F2 activation antigen and required activation by anti-# antibody, which did not of itself induce proliferation, but which acted in synergy with BCGF for substantial proliferation of the B cells. These studies thus provide a useful model of human B cell activation, proliferation, and differentiation and allow a more precise delineation of each phase in this cascade.
